Is SANGAMO THERAPEUTICS, INC (SGMO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 21.8% / 30% | 29.9% / 30% | 3.3% / 30% | 10.14% / 5% | ✗ NOT HALAL |
| DJIM | 21.8% / 33% | 29.9% / 33% | 3.3% / 33% | 10.14% / 5% | ✗ NOT HALAL |
| MSCI | 30.1% / 33% | 41.2% / 33% | 4.5% / 33% | 10.14% / 5% | ✗ NOT HALAL |
| S&P | 21.8% / 33% | 29.9% / 33% | 3.3% / 33% | 10.14% / 5% | ✗ NOT HALAL |
| FTSE | 30.1% / 33% | 41.2% / 33% | 4.5% / 50% | 10.14% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -219.1% | |
| Operating Margin | -6119.3% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -480.0% | |
| Return on Assets (ROA) | -68.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$67M |
| Free Cash Flow | -$67M |
| Total Debt | $31M |
| Debt-to-Equity | 407.2 |
| Current Ratio | 0.9 |
| Total Assets | $102M |
Price & Trading
| Last Close | $0.34 |
| 50-Day MA | $0.39 |
| 200-Day MA | $0.49 |
| Avg Volume | 6.0M |
| Beta | 1.3 |
|
52-Week Range
$0.31
| |
About SANGAMO THERAPEUTICS, INC (SGMO)
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is SANGAMO THERAPEUTICS, INC (SGMO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), SANGAMO THERAPEUTICS, INC is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is SANGAMO THERAPEUTICS, INC's debt ratio?
SANGAMO THERAPEUTICS, INC's debt ratio is 21.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 30.1%.
What are SANGAMO THERAPEUTICS, INC's key financial metrics?
SANGAMO THERAPEUTICS, INC has a market capitalization of $119M, and revenue of $58M. Return on equity stands at -480.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.